Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive August 1, 2014	EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire? Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.
Pharmaceutical Executive October 1, 2012 Peter O'Donnell	Richard Bergstrom -- Europe's Medicine Man The new head of the European Federation of Pharmaceutical Industries and Associations faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics.
Pharmaceutical Executive July 1, 2011	Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy.
Pharmaceutical Executive January 1, 2012	Here's to a Happier New Year? A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
Pharmaceutical Executive June 1, 2011	A Lack of Information Why has the EU still not managed to update its rules on information about medicines?
Pharmaceutical Executive September 1, 2014	Peril, Not Progress on Transatlantic Trade Deal Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.
Pharmaceutical Executive September 1, 2012	Patients Wade Into the Pricing Debate Europe's fiscal crisis is becoming a new rallying cry for patient groups, but regional unity is still elusive.
Pharmaceutical Executive June 1, 2012	Europe Responds to Medical Device 'Crisis' A recent medical device controversy in France has pushed European health ministers to agree on a crisis management program for the troubled sector.
Chemistry World October 29, 2007 Arthur Rogers	Deal to Allow Poor Nations Better Access to Cheap Drugs MEPs belatedly approved EU ratification of a 2005 World Trade Organization protocol on compulsory licensing -- potentially paving the way for developing countries to order generic drugs from manufacturers abroad without infringing patent rights.
Pharmaceutical Executive September 1, 2013	T-TIPing the Balance in Industry's Favor By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Pharmaceutical Executive April 1, 2011	Dalli's Formula Fails the Efficacy Test EU leadership on pharma policy leaves many wondering of the right man is at the helm.
Pharmaceutical Executive May 1, 2011	Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
Pharmaceutical Executive August 1, 2013	Pharma Bids for European Funding in New Research Program The euro 70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive October 1, 2014 William Looney	IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.
Pharmaceutical Executive December 1, 2011	Europe's Transparency Directive Revisited The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
Pharmaceutical Executive November 1, 2011	Europe Tackles 'Advertising in Disguise' Fears The EC's latest proposals have thrown water on Europe's fiery Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
Pharmaceutical Executive October 1, 2014	Eruptions on the Drug-Pricing Horizon in Europe An escalating political debate over pharma pricing and reimbursement nears the boiling point.
Pharmaceutical Executive September 1, 2014 William Looney	Ireland's Celtic Tiger: Back on the Hunt Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Pharmaceutical Executive May 1, 2007 Sarah Houlton	Global Report: Pure and Simple The european union is set to overhaul the way it monitors drug safety to help make sense of a decentralized system that has been criticized for being ineffective. Will the EC's upcoming drug-safety plan be just what the doctor ordered or end up an indecent proposal?
Pharmaceutical Executive March 1, 2011 William Looney	John Castellani: Industry's Level Bet on a Dizzying Future Can PhRMA's own business model sync with industry's Pharm Exec takes a closer look at PhRMA's new leadership.
Chemistry World August 17, 2015 Anthony King	Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending
Pharmaceutical Executive April 1, 2012	Country Report: Ukraine Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts. But what has such rapid development done for the country's healthcare?
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World December 14, 2009 Ned Stafford	New approach for EU research called for Research experts have called for EU leaders to make 'radical improvements' in research policy following an assessment of the current state of European science.
Pharmaceutical Executive February 1, 2006 Sarah Houlton	Global Report: Moving Towards Generic Biologics The European Medicines Agency hopes to complete its guidelines for the approval of biosimilar drugs early this year, paving the way for the approval of biogenerics - and a potential goldmine for the generics companies.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Chemistry World November 14, 2014 Angeli Mehta	European commission scraps chief scientific adviser post, dismaying scientists Leading scientists from across Europe have condemned the decision by the new president of the European commission to scrap the post of chief scientific adviser
Pharmaceutical Executive December 1, 2010 William Looney	In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Chemistry World January 6, 2014 Sarah Houlton	Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed.
Chemistry World August 2, 2007 Victoria Gill	Europe Poised for a Surge in Generic Drugs The European Medicines Agency's Committee for Medicinal Products for Human use has recommended the approval of a schizophrenia treatment which is the first generic drug to be assessed under Europe's centralized procedure.
Pharmaceutical Executive November 1, 2008 Sarah Houlton	Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace.
Parameters Autumn 2004 Alan W. Dowd	A Different Course? America and Europe in the 21st Century Understanding the changes and challenges within Europe could help Americans respond to the changes and challenges facing the transatlantic community.
Chemistry World May 3, 2007 Arthur Rogers	Uncertain Future for Europe's MIT Rival Plans for a European Institute of Technology to rival the U.S. Massachusetts' Institute of Technology are in disarray amid fears the EU flagship could be reduced to a virtual university.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
BusinessWeek November 15, 2004 John Rossant	And Europe Thinks The U.S. Is A Mess? The European Union is so polarized that further integration may well prove impossible.
Pharmaceutical Executive September 1, 2005 Sarah Houlton	Global Report: Kids 'R' EU After years of delay, the European Parliament is ready to vote on pediatric-testing legislation.
Chemistry World July 15, 2014 Emma Stoye	Public--private research partnerships to tackle Europe's big problems The European Union will invest euro 7.3 billion in seven newly launched public -- private partnerships as part of its Horizon2020 research funding program.
Chemistry World June 19, 2014 Ned Stafford	EU plan to let member states decide on GM The European council of environment ministers would allow member states to go it alone and ban the cultivation of genetically modified crops.
Pharmaceutical Executive July 1, 2005 Sarah Houlton	Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one.
Chemistry World February 18, 2014 Ned Stafford	GM maize poised for approval in Europe The European commission is on the verge of authorizing a genetically modified maize for cultivation after ministers from EU member nations last week failed to muster a large enough majority to reject the crop.
Pharmaceutical Executive October 1, 2011	The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work.
Pharmaceutical Executive July 1, 2014	Europe Gears Up to Attack Counterfeit Medicines -- But Only Some of Them Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.